NCT06796803View on ClinicalTrials.gov

Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

398

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

February 20, 2028

Study Completion Date

February 28, 2030

Conditions

Potentially Resectable Hepatocellular Carcinoma

Interventions

DRUG

camrelizumab combined with rivoceranib and HAIC

systemic therapy combined with locoregional theraphy as conversion therapy

DRUG

camerlizumab + rivoceranib

systemic therapy

Trial Locations (1)

200000

Zhongshan Hospital, Shanghai

All Listed Sponsors

collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

Shanghai Zhongshan Hospital

OTHER

NCT06796803 - Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) | Biotech Hunter | Biotech Hunter